Biovinate Drug Interactions

Aluminum: Aluminum reacts with carboplatin causing a black precipitate to form. Do not use needles, syringes, catheters or IV administration sets that contain aluminum parts that may come in contact with carboplatin when used for the preparation or administration of the drug.
Oral anticoagulants: Treatment with anticoagulants is frequent due to the increased thrombotic risk in cases of tumoral diseases. International normalized ratio (INR) should be monitored frequently in patients treated with anticoagulants since intra-individual variability of the coagulability during diseases and the possibility of interaction between oral anticoagulants and antineoplastic drugs are likely to occur.
Myelosuppressive Therapy or Radiation Therapy: Concomitant use of carboplatin may potentiate the hematologic toxicity of the other agents and vice versa. Patients receiving concurrently or who have received myelosuppressive or radiation therapy should be carefully monitored. Dosage of the drug and time of administration should be managed to minimize additive toxic effects.
Phenytoin, Fosphenytoin: Phenytoin digestive absorption is reduced by carboplatin hence increasing the risk of exacerbation of convulsion. Also there is risk of toxicity enhancement or loss of efficacy of carboplatin due to increased hepatic metabolism of phenytoin.
Nephrotoxic or Ototoxic Agents (e.g., aminoglycosides, vancomycin, capreomycin and loop diuretics): Concurrent administration may increase carboplatin's nephrotoxicity and ototoxicity risks.
Emetogenic Agents: an increased incidence of emesis has been associated with concomitant use of carboplatin and other emetogenic drugs or when carboplatin is administered to patients who previously received emetogenic therapy.
Vaccines: Yellow fever vaccine is contraindicated with carboplatin. Concomitant use of live attenuated vaccines with carboplatin is not recommended because it may result in systemic and possible fatal disease. This risk is increased in patients who are already immunocompromised by their underlying disease.